# A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

> **NCT03582033** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 83 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** SEA-BCMA
- **DRUG:** dexamethasone
- **DRUG:** pomalidomide

## Key facts

- **NCT ID:** NCT03582033
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-01
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Study closed due to portfolio prioritization
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03582033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03582033, "A Safety Study of SEA-BCMA in Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03582033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*